Hyderabad, 20^th January 2021– Esperer Onco Nutrition evidence based Responsible Nutrition (E2RN) hosted a virtual symposium on Vaccinations for cancer patients: What to know before the Corona vaccination recently. The host of this virtual discussion was Mr Raktim Chattopadhyay, Founder & CEO of Esperer Onco Nutrition with 10 speakers from the UK, USA, and India.

Over 100 participants attended the symposium; the webinar was addressed to cancer patients and their family members along with relevant clinicians. The symposium offered a presentation of important topics such as, first-hand experience of tackling UK variant strain, COVID-19 vaccine and Cancer and India v/s USA & UK experience – difference and similarities.

Dr. Vivek Shrivastav, Vice President Research & Development and Operations at Esperer Onco Nutrition said, “Not so incredibly, there’s a lot of confusion among cancer patients — as well as their oncologists and caregivers — as to whether the vaccine is a good idea or a bad idea for somebody dealing with cancer. Patients with cancer are particularly vulnerable to COVID-19 because of the immunocompromising nature of cancer treatments. On top of that, progressing cancer itself depletes the immune system and leaves patients susceptible to infection. Cancer patients should be early in the vaccination process”.

He added, “Fundamentally, we should try to stop community transmission, and to focus on groups at high-risk for transmission and complications first. We should prioritize high-risk groups, but we also need to do it in a way that’s even-handed. We’re fighting a pandemic where cancer patients are at four-five-times greater risk for fatality than others. It’s a risk-benefit equation. Their risk from COVID-19 is exceptionally high and cancer cases should have a definite regimen of vaccination, which may further consolidate by carrying out scientific research, applied research and clinical studies.”

In general, vaccines are not recommended during chemotherapy or radiation therapy. Vaccines require a healthy immune system that can recognize and kill disease-causing germs. And it takes a healthy immune system at least 2 weeks from the time of vaccination to start recognizing and killing germs. That means vaccination timing is just as important as getting the vaccine itself.

Dr Purvish Parikh, Group Oncology Director Academic at Shelby Cancer and Research Institutes, Mumbai, said “We recommend that all cancer patients get vaccinated against COVID-19. This is in line with recommendations by important international Oncology societies. Vaccination should be taken even by those patients who have been previously exposures to the virus or have antibody titres. Timing of the vaccination need to take into consideration patient specific factors – like being on active chemotherapy, performances status, severity of uncontrolled comorbidity, and pregnant or lactating mothers.”

Esperer Nutrition is superintended to understand and brainstorm the cancer related topics through its E2RN programme and various attributes on COVID 19 vaccine and cancer were debated.

The post Winning over the two Cs – COVID-19 and Cancer appeared first on Health Vision.

Wound healing, substitution of destroyed or damaged tissue by newly produced one, can classically be divided into four steps: haemostasis, inflammation, cell proliferation and tissue maturation. With each successive phase in the normal sequence of wound healing, the immune system orchestrates a wide variety of processes. Different immune cells have been shown to peak in number and activity at different times during the healing cascade, thus helping distinguish the different stages of the process.

As the ardent votaries in the laboratories as well as clinics have witnessed in past decades, enormous efforts have been directed to develop beneficial techniques for achieving speedy recovery minimizing the scar, ensuring function preservation. To avert infection and stimulate a proper healing process, the classical approach for wound management still remains as topical administration of antibacterial or colloidal agents.

The healing process may be dismayed by both internal and external factors, viz., necrotic tissue, pathogen contamination, entrapment of non-native materials, comorbidities such as diabetes mellitus, etc., causing a delay in each phase of recovery. Often times, skirmishes brake out when wound closure gets affected by colonization of an invading microbial agent.

It turns out that, due to synergistic bacterial development pattern, chronic wound infections are polymicrobial. On the other hand, acute wounds are generally associated with a diminished microbial load, scab formation and immune cells infiltration in the initial phase, while healing is correlated with re-epithelialization, angiogenesis and fibroblast migration.

Growing knowledge of the physiologic role of various nutritional elements has led to the recognition of certain nutrients like amino acids (glutamine etc.), vitamins (A, C, E etc.), antioxidants (beta-carotene, coenzyme Q10 etc.), fatty acids (Omeag-3. medium chain triglycerides etc.), trace elements, minerals etc. in wound management.

It is obvious that a higher level of attention and research are required to evaluate the microbial effects on wound-healing ability, potential new therapeutic agents that can regulate the cross-talk between microflora, pathogens and the innate immune response, and lead to wound healing acceleration. Current research has witnessed a major impact of commensal microorganisms, beneficial bacteria, on multiple physiological processes including protection against pathogenic invasion and infection as well as immunomodulatory effects in tissue repair.

Of many, Lactic acid bacteria (LAB) and bifidobacteria are some of the most widely studied species that improve host welfare and are most commonly referred to as probiotics. To this end, Esperer Onco Nutrition (EON) is rejoicing the launch of a new product, namely, Liss WH which is augmented by probiotic blend (Lactobacillus acidophilus, Lactobacillus casei, Lactobacillus fermentum and Bifidobacterium bifidum) having multifarious functions namely, collagen synthesis, H₂O₂ production, enhanced absorption of dietary vitamin D and E, induction of crucial cytokines (TNFα, IFN-γ, IL-10, etc.), increase in neutrophil infiltration, anti-microbial activity, etc.

It is also enriched with natural antioxidants and immuno-nutrients such as β-carotene, coenzyme Q10 and mixed tocopherols which help in the prevention of infections in the surgical wounds, thus speeding up the recovery after cancer surgery. The osmolarity (280 to 300 mosmol /Litre) is suitable for enteral tube feeding and better nutrient absorption. Furthermore, EON intends to extend its research towards exploring nano-nutraceutical intervention for use in surgical wound healing in recent future. EON believes that the combination of nanotechnology with the existing protocol can pave the way for future medication of wound management.

Dr. Anubhab Mukherjee
Principal Scientist, R&D
Esperer Onco Nutrition (EON) Pvt. Ltd

The post Nutraceutical intervention towards wound healing after cancer surgery appeared first on Health Vision.

Mumbai, April 17, 2020: Esperer Onco Nutrition Pvt Ltd (EON), a pioneer in bringing comprehensive nutritional portfolio to oncology, announced significant amount of fund raising from Zenfold Ventures. Talking about the stake sale Mr. Raktim Chattopadhyay, Founder & CEO Esperer Onco Nutrition Pvt Ltd said, “Onco-nutrition is one of the critical complementary therapy for cancer patients. EON has several patentable products that are used to bring optimal efficacy to the main therapy by complementing it with nutrition to add  better quality of health and life.

Esperer nutri-therapies provide the much needed body strength for onco-patients to overcome the side effect of primary treatment providing better outcomes for onco-patients. Explaining the rationale behind the investment, Mr. Arun Dubey Managing Partner at Zenfold Ventures said “Zenfold’s investment & partnership outlook is sector and stage agnostic. At present some of the ventures we are building ,are in the space of Nutraceuticals. We believe EON has a very scientifically backed approach to nutrition and has strong capabilities to execute of the vision.”

“We are thrilled to have Zenfold Ventures as a strategic investor in EON, and this infusion will help us reach more cancer patients in a shorter time.”We plan to use the latest funds to expand our reach to the US and European markets and also to build a world-class talent pool”, added Mr. Chattopadhyay. Esperer nutrition has already expanded its team of experts in scientific and R& D departments and will also be adding key people in finance and marketing and supply chain.

The strategy of EON is based on clinical validations of nutraceutical elements which are used for both onco-management and prevention. Over the next two yearsEON plans to have  more technical collaborations with international technical authorities to expand its research and product portfolio.

Mr. Chattopadhyay explained, “EON takes responsible nutrition very seriously and studies it with respect to the science of biochemistry. With the scientific platform in place, the discovery of modified nutraceutical portfolio has been developed to suit different conditions of patients undergoing chemo. Esperer nutrition takes pride in having developed the world’s first condition-specific nutrition for oncology to impact quality health outcome.”

www.esperernutrition.com 

The post Zenfold Ventures takes equity stake in Esperer Onco Nutrition appeared first on Health Vision.

Now we are more clear that malnutrition and nutritional alterations, common complications of human immunodeficiency virus infection, include disorders of food intake, nutrient absorption, and intermediary metabolism and play a significant and independent role in morbidity and mortality. This simple understanding is the key in any innovative research or pandemic situation like COVID 19, NIPA, Ebola etc. Human body physiology is equipped to tackle any infection proactively provided we are aware of some basic precaution and give priority to our nutritional health.

Important to know about CORONA:

• –  NCV (Covid 19) is a subtype of Corona Virus Family
• –  These viruses are responsible for flu like respiratory diseases
• –  Previous Corona Virus diseases were SARS & MERS
• –  They are zoonotic (transmitted from animals)

Spread:

1. Droplet (cough)
   2. Fomite (hand to mouth)
2. Ingestion (food borne – very rare)

Diagnosis:

1. Real Time PCR Assay – Done on Sputum / throat swab / body fluids.
2. Supportive test – Complete Blood Count, Chest X-ray, Chest CT Scan.

Treatment:

No specific treatment, Isolation care, No vaccine available Supportive Care (fluids etc.)
Good Nutrition

Know this:

1. Does not spread from properly cooked non veg food
2. Does not spread from Chinese food / carrier
3. No risk from pets
4. Symptom free people need not use mask
5. Every cough and cold is not Corona
6. Mild and Moderate disease is curable with supportive care

Mr. Raktim Chattopadhyay

Founder & CEO, Esperer Onco Nutrition

 Post graduate in Human Physiology & specialised in Medical Nutrition.

The post Good Nutrition; Infection and Corona – Basic understanding appeared first on Health Vision.